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Dear Editor, Castellucci et al.1 report on the prospective comparison of multiparametric 
prostate magnetic resonance imaging (mp-MRI) cognitive targeted biopsies versus standard 
randomized transrectal ultrasound-guided biopsies (TRUSGB) in the diagnosis of prostate 
cancer (PCa) in 168 biopsy-naïve patients. Patients with elevated PSA levels and/or abnormal 
digital rectal examination were included, and all patients underwent mp-MRI prior to TRUSGB 
and cognitive 2-cores targeted biopsy, if needed. The authors showed that the overall cancer 
detection rate was 35.7%, 28.6% and 41.1% in TRUSGB, cognitive biopsy and combination 
(TRUSGB + cognitive) technique respectively, whilst the clinical significant cancer detection 
rate (based on biopsy Gleason score only) was 55%, 62.5% and 59.4% respectively, with a 
higher sensitivity, specificity, positive, and negative predictive value compared to the 
standard approach. The authors concluded that the mp-MRI cognitive targeted approach in 
naïve patients detected a higher number of intermediate and high-risk PCas compared to the 
standard approach. This study is not without limitations, but it has the value of highlighting 
the use of mp-MRI as a triage test in patients suspected of having PCa. Indeed, while the role 
of mp-MRI and target biopsies is now consolidated in re-biopsy scenarios,2 its exact role in 
biopsynaïve patients is still being discussed. The actual PCa diagnostic scenario is represented 
by an existing test, the standard untargeted 12-cores TRUSGB. The advent of mp-MRI has 
changed the approach to prostate biopsy, allowing clinicians to direct biopsies to suspected 
lesions rather than performing them randomly. mp-MRI , followed by target biopsy if needed, 
could add-on or replace the existing test. In the study of Castellucci et al., and in most studies 
conducted to determine the diagnostic value of target biopsy, patients underwent cognitive 2-
cores targeted biopsy combined with TRUSGB in the same session, representing an add-on to 
the existing standard test in the detection rate of significant PCa. Another approach to the 
problem is to evaluate the role of mp-MRI as an initial test which will replace the existing 
standard diagnostic process. Porpiglia et al. recently published a randomized controlled trial 
comparing PCa detection rates between a new diagnostic pathway, based on mp-MRI and, in 
case of suspected lesions, subsequent MRI/TRUS fusion software-guided target biopsy alone, 
with the standard pathway in biopsy-naïve men with PSA levels ≤15 ng/mL, and negative 
digital rectal examination.3 They reported higher detection rates for the mp-MRI pathway in 
terms of overall and clinically significant PCas, concluding that mpMRI could be considered 
prior to a first prostate biopsy. In our opinion, the use of mp-MRI and target biopsies as a 
first-line test will become the standard of care in biopsy-naïve men if it replicates the results 
of target biopsies in re-biopsy scenarios, outperforming the standard biopsy to: 1) detect 
clinically significant PCas and not detect clinically insignificant PCa; 2) detect PCa with fewer 
number of cores; 3) improve the quality of samples, both in core length and in Gleason 
grading.4 Moreover, the use of mp-MRI and target biopsies early in the pathway of PCa 
diagnosis could improve the selection of candidates for active surveillance 5 or minimally 
invasive treatments such as focal therapy.6 This, together with a better localization and 
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monitoring of the disease process over time, could increase the enrollment of patients and the 
safety of these treatments. Further evidence will be acquired in the near future when the 
results of ongoing trials will be available and will better clarify the role of mp-MRI and target 
biopsies in the pathway of PCa diagnosis. 
 
